Zoetis Inc (ZTS)
割安ファンダメンタル
72
株価
$69.89
時価総額
$29.52B
パート1 · 企業の価値
概要
Zoetis Inc. engages in the discovery, development, manufacture, and commercialization of medicines, vaccines, diagnostic products and services, biodevices, genetic tests, and precision animal health solutions for the animal health industry in the United States and internationally. The company commercializes products primarily across companion animals comprising dogs, cats, and horses; and species, including livestock, such as cattle, swine, poultry, fish, and sheep. It also offers parasiticides, vaccines, dermatology, anti-infectives, pain and sedation, other pharmaceutical, and animal health diagnostics. In addition, the company provides animal health diagnostics, including point-of-care diagnostic products, instruments and reagents, rapid immunoassay tests, reference laboratory kits and services, and blood glucose monitors; and other non-pharmaceutical products, which include nutritionals, as well as products and services in biodevices, genetic tests, and precision animal health. It markets its products to veterinarians, livestock producers, and pet owners. The company has collaborated with Blacksmith Medicines, Inc. to discover and develop novel antibiotics for animal health. Zoetis Inc. was incorporated in 2012 and is headquartered in Parsippany, New Jersey.
No editorial profile for this company yet
Direct competitors
Who this company fights with for the same customers
No editorial profile for this company yet
No competitor list for this company yet.
貸借対照表と流動性
売上高
$9.53B
直近12か月（2026/6/30まで）
純利益
$2.64B
直近12か月（2026/6/30まで）
フリーキャッシュフロー
$2.28B
自己資本合計
$3.42B
負債合計
$12.07B
流動比率
3.08
利払い倍率
-
負債/EBITDA
2.27
一株当たり利益（EPS）
売上高と純利益
フリーキャッシュフロー
収益内訳
財務推移表
利益率の推移
負債の推移
負債の重さ
成長率グリッド
成長率 — 売上高
適正価値の推定
適正価値
$112.17
現在株価
$69.89
安全マージン
+37.7%
適正価値レンジ
$72.91 - $151.42
使用した評価手法間のばらつきであり、統計的に較正された信頼区間ではありません。
推定方法
バリュエーション指標
P/E レシオ
11.29
ROE
78.3%
P/B レシオ
9.07
P/FCF
12.33
粗利益率
71.7%
ROIC
-
収益性レーダー
価値創造（経済的モート）
ROIC
-
WACC
6.8%
ROIC − WACC
-
ファンダメンタル分析基準
合格（18）
- EPS shows upward trend
- EPS CAGR 19.62%
- Gross Margin 71.7%
- P/FCF 12.33
- Debt/Equity ratio
- Positive Free Cash Flow
- CapEx intensity
- Current Ratio
- Debt/EBITDA
- Return on Tangible Assets
- ROE 69.3%
- Revenue Growth 5Y 7.2%
- Analyst Consensus 50% Buy
- PEG Ratio 0.93
- Earnings Quality (OCF/NI) 1.08
- Share Dilution -2.3%
- Net Margin Trend 27.7% vs 27.6%
- Piotroski F-Score 6/9
不合格（6）
- Price CAGR 3.15%
- P/B Ratio 9.07
- Low reliance on intangibles
- Price below Graham Number
- DCF valuation (Overvalued)
- Earnings Surprise avg 0.5%
データなし（4）
- ROIC NaN%
- Dividend Payout NaN%
- Operating Margin NaN%
- Interest Coverage
Piotroski F-スコア
まちまちのシグナル：一部の領域に注意が必要
利益の質
高品質：利益はキャッシュに裏付けられている
株式希薄化
株式を買い戻している。株主に友好的
機関投資家の保有
ガバナンス
経営陣
| 氏名 | 役職 | 年齢 |
|---|---|---|
| Ms. Kristin C. Peck | CEO & Director | 54 |
| Ms. Roxanne Lagano | Executive VP, General Counsel & Corporate Secretary | 60 |
| Mr. Wetteny N. Joseph CPA | Special Advisor to the CEO | 53 |
| Dr. Robert J. Polzer Ph.D. | Scientific Advisor | 56 |
| Mr. Jamie Brannan | Executive VP & Chief Commercial Officer | 52 |
| Mr. James K. Saccaro | Executive VP, CFO & COO | 52 |
| Mr. Keith Sarbaugh | Executive VP & Chief Digital and Technology Officer | 46 |
| Mr. Steven Frank | Vice President of Investor Relations | - |
| Ms. Julie A. Fuller | Executive VP, Chief Human Resources Officer & Global Operations | 52 |
| Mr. Abhay U. Nayak | Executive VP & President of U.S. Commercial Operations | 37 |
監査リスク
5
取締役会リスク
2
報酬リスク
6
株主権利リスク
7
パート2 · 株価と買い時
この部分は企業に価値があるかを判断するものではありません。ファンダメンタルズに納得したうえで、いつ買うかを選ぶためのものです。内容：テクニカル分析、ポテンシャル、過去のドローダウン、ガンマエクスポージャー。
業績推移
via SEC EDGAR
Latest News
Recent headlines for ZTS, sourced from Markets Gazette.
- 5/10/2026NEGATIVEZoetis, Insmed, And HubSpot Are Among Top 10 Large-Cap Losers Last Week (May 4-May 8): Are The Others In Your Portfolio?
Zoetis Inc. was among the top large-cap decliners last week, experiencing a significant sell-off. This downturn was primarily attributed to weak earnings reports, cautious forward guidance from the company, and subsequent reductions in analyst price targets. The broader market sentiment also played a role, with declines seen across healthcare, software, networking, and industrial sectors. Investors are advised to monitor Zoetis's upcoming earnings calls and management commentary for signs of a potential turnaround or further headwinds.
via Markets Gazette